Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant promise » significant rise (Expand Search), significant progress (Expand Search), significant positive (Expand Search)
promise decrease » point decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant promise » significant rise (Expand Search), significant progress (Expand Search), significant positive (Expand Search)
promise decrease » point decrease (Expand Search)
-
2281
-
2282
Verification of PLUS CYCLE<sup>®</sup> signals during presumed sleep periods.
Published 2025Subjects: -
2283
-
2284
-
2285
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2286
-
2287
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2288
-
2289
-
2290
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2291
-
2292
-
2293
-
2294
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2295
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2296
-
2297
-
2298
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2299
-
2300